Large study reveals how Lutetium-177 is used in real life for prostate cancer

This study looked at 1,247 patients in the United States with a type of advanced prostate cancer called metastatic castration-resistant prostate cancer (mCRPC) who were treated with a drug called Lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617). The goal was to understand the patients' characteristics, how they were treated, and what happened to them in real-world settings, not in a controlled clinical trial. The study found that most patients had received other treatments before starting Lutetium-177, and it tracked how many doses they received and whether their PSA levels dropped after treatment.